Needham & Company Reiterates Buy on Progenics Pharma (PGNX); Anticipates Oral Relistor Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Progenics Pharma (PGNX) Tops Q4 EPS by 4c
March 11, 2016 8:02 AM ESTProgenics Pharma (NASDAQ: PGNX) reported Q4 EPS of ($0.10), $0.04 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $5.1 million versus the consensus estimate of $2.25 million.
For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.
... MoreTrading Radar for 3/11: Genesco (GCO), Hibbett Sports (HIBB), The Buckle (BKE), Lifetime Brands (LCUT) Report
March 10, 2016 2:27 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EST
Earnings:
Century Casinos (Nasdaq:... More
